Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $54.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-26
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $3.00K.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $51.00K, a 75.86% increase year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $0.00.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $29.00K.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $54.00K, a 55.37% decline from fiscal 2024.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $121.00K.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.74M, a 70.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $54.00K derived: sum of 2 quarters · filed 2026-03-26 | $54.00K 10-K · filed 2026-03-26 | |
| 2025-09-30 | $51.00K 10-Q · filed 2025-11-06 | $51.00K 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $29.00K derived: sum of 2 quarters · filed 2026-03-26 | $120.00K derived: sum of 3 quarters · filed 2026-03-26 | $121.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $29.00K 10-Q · filed 2025-11-06 | $120.00K derived: sum of 2 quarters · filed 2025-11-06 | $121.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $91.00K 10-Q · filed 2024-08-08 | $91.00K 10-Q · filed 2024-08-08 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $21.00K derived: sum of 2 quarters · filed 2024-03-26 | $1.62M derived: sum of 3 quarters · filed 2024-03-26 | $1.65M derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.62M derived: sum of 2 quarters · filed 2024-03-26 | $1.65M derived: sum of 3 quarters · filed 2024-03-26 | $2.74M 10-K · filed 2024-03-26 |
| 2022-09-30 | $1.60M 10-Q · filed 2023-11-02 | $1.63M derived: sum of 2 quarters · filed 2023-11-02 | $2.72M 10-Q · filed 2023-11-02 | $4.19M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $36.00K 10-Q · filed 2023-08-08 | $1.12M 10-Q · filed 2023-08-08 | $2.59M derived: sum of 3 quarters · filed 2023-08-08 | $2.62M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.08M 10-Q · filed 2023-05-04 | $2.55M derived: sum of 2 quarters · filed 2023-05-04 | $2.58M derived: sum of 3 quarters · filed 2023-05-04 | $2.58M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.50M derived: sum of 2 quarters · filed 2023-03-23 | $1.50M derived: sum of 3 quarters · filed 2023-03-23 | $1.61M 10-K · filed 2023-03-23 |
| 2021-09-30 | $26.00K 10-Q · filed 2022-11-14 | $26.00K derived: sum of 2 quarters · filed 2022-11-14 | $140.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $114.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $22.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |